Class II · Moderate risk
Minivelle (estradiol transdermal system)
Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.
FDA Drug Recalls
1,590 recalls, newest first
Class II · Moderate risk
Minivelle (estradiol transdermal system)
Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.
Class III · Low risk
Bupropion Hydrochloride ER Tablets
Failed impurities/ degradation specifications: Out-of-specification results were observed in the meta-chlorobenzoic acid impurity in batches 18 months or older from date of manufacture in the 90 count bottle size.
Class II · Moderate risk
Class III · Low risk
Pramipexole dihydrochloride extended release tablets
Failed impurities/degradation specifications: Finished product contain a known product impurity about current specification levels.
Class II · Moderate risk
Synjardy (empagliflozin and metformin hydrochloride)
Cross Contamination With Other Products:
Class II · Moderate risk
Tizanidine HCl Tablets
Presence of Foreign Tablets/Capsules: Glimepiride tablet was found in a bottle of Tinzadine Hcl Tablets .
Class II · Moderate risk
Arthritis Pain Relief Homeopathic Formula
CGMP Deviations: products manufactured by contract manufacturer under conditions that could result in possible microbial contamination.
Class II · Moderate risk
Colds & Flu Response Homeopathic Formula
CGMP Deviations: products manufactured by contract manufacturer under conditions that could result in possible microbial contamination.
Class II · Moderate risk
Allergy & Hay Fever Relief Homeopathic Formula
CGMP Deviations: products manufactured by contract manufacturer under conditions that could result in possible microbial contamination.
Class II · Moderate risk
Muscle & Joint Pain Relief Homeopathic Formula
CGMP Deviations: products manufactured by contract manufacturer under conditions that could result in possible microbial contamination.
Class II · Moderate risk
Diarrhea Response Homeopathic Formula
CGMP Deviations: products manufactured by contract manufacturer under conditions that could result in possible microbial contamination.
Class II · Moderate risk
Sore Throat & Laryngitis Response Homeopathic Formula
CGMP Deviations: products manufactured by contract manufacturer under conditions that could result in possible microbial contamination.
Class II · Moderate risk
Sinus Response Homeopathic Formula
CGMP Deviations: products manufactured by contract manufacturer under conditions that could result in possible microbial contamination.
Class II · Moderate risk
Skin Irritation & Itch Response Homeopathic Formula
CGMP Deviations: products manufactured by contract manufacturer under conditions that could result in possible microbial contamination.
Class II · Moderate risk
NeoRelief for Muscle Cramping & Restlessness Homeopathic Topical Gel
CGMP Deviations: finished product produced with active ingredients recalled by the manufacturer, King Bio Inc., due to water contamination issues that could potentially affect the quality of this product.
Class II · Moderate risk
Thyroid powder
CGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.
Class III · Low risk
Argatroban Injection
Failed Impurities/Degradation Specifications; Out of specification stability testing results at the 18 month time point
Class II · Moderate risk
Thyroid
CGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.
Class II · Moderate risk
Thyroid
CGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.
Class II · Moderate risk
Thyroid
CGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.
Class III · Low risk
MethylPREDNISolone Tablets
Failed Stability Specifications: An out-of-specification result was obtained during 18-month stability testing for assay.
Class I · High risk
Furosemide 100 mg added to 0.9% Sodium Chloride 100 mL Injection
Presence of Precipitate: Customer complaint for visible precipitate in product believed to be the active ingredient furosemide.
Class III · Low risk
Levonorgestrel and Ethinyl Estradiol Tablets
Labeling: Not Elsewhere Classified-Incorrect NDC and product name identified on blister packs.
Class I · High risk
Norepinephrine 4 mg
Subpotent Drug: Product may not have the active ingredient present in the bag.